Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1989 4
1990 2
1991 3
1992 1
1993 8
1994 4
1995 4
1996 8
1997 6
1998 7
1999 12
2000 22
2001 19
2002 13
2003 23
2004 21
2005 17
2006 14
2007 25
2008 18
2009 16
2010 20
2011 21
2012 15
2013 18
2014 14
2015 9
2016 11
2017 11
2018 10
2019 9
2020 13
2021 11
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

391 results

Results by year

Filters applied: . Clear all
Page 1
Hypertriglyceridaemia: an update.
Wierzbicki AS, Kim EJ, Esan O, Ramachandran R. Wierzbicki AS, et al. J Clin Pathol. 2022 Dec;75(12):798-806. doi: 10.1136/jclinpath-2021-207719. Epub 2022 Jun 16. J Clin Pathol. 2022. PMID: 35710321 Review.
Familial hypercholesterolaemia.
Defesche JC, Gidding SS, Harada-Shiba M, Hegele RA, Santos RD, Wierzbicki AS. Defesche JC, et al. Among authors: wierzbicki as. Nat Rev Dis Primers. 2017 Dec 7;3:17093. doi: 10.1038/nrdp.2017.93. Nat Rev Dis Primers. 2017. PMID: 29219151 Review.
Lipidomics in diabetes.
Kim EJ, Ramachandran R, Wierzbicki AS. Kim EJ, et al. Among authors: wierzbicki as. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):124-130. doi: 10.1097/MED.0000000000000704. Curr Opin Endocrinol Diabetes Obes. 2022. PMID: 34954721 Review.
Lipid-lowering agents.
Ewang-Emukowhate M, Wierzbicki AS. Ewang-Emukowhate M, et al. Among authors: wierzbicki as. J Cardiovasc Pharmacol Ther. 2013 Sep;18(5):401-11. doi: 10.1177/1074248413492906. Epub 2013 Jun 27. J Cardiovasc Pharmacol Ther. 2013. PMID: 23811423 Review.
Triglycerides and cardiovascular disease.
Esan O, Wierzbicki AS. Esan O, et al. Among authors: wierzbicki as. Curr Opin Cardiol. 2021 Jul 1;36(4):469-477. doi: 10.1097/HCO.0000000000000862. Curr Opin Cardiol. 2021. PMID: 33797418 Review.
Radiotherapy, chemotherapy and atherosclerosis.
Min SS, Wierzbicki AS. Min SS, et al. Among authors: wierzbicki as. Curr Opin Cardiol. 2017 Jul;32(4):441-447. doi: 10.1097/HCO.0000000000000404. Curr Opin Cardiol. 2017. PMID: 28306672 Review.
Atorvastatin.
Wierzbicki AS. Wierzbicki AS. Expert Opin Pharmacother. 2001 May;2(5):819-30. doi: 10.1517/14656566.2.5.819. Expert Opin Pharmacother. 2001. PMID: 11336625 Review.
Investigating raised creatine kinase.
Kim EJ, Wierzbicki AS. Kim EJ, et al. Among authors: wierzbicki as. BMJ. 2021 Jun 23;373:n1486. doi: 10.1136/bmj.n1486. BMJ. 2021. PMID: 34162592 Review. No abstract available.
Genetic risk scores in lipid disorders.
Wierzbicki AS, Reynolds TM. Wierzbicki AS, et al. Curr Opin Cardiol. 2019 Jul;34(4):406-412. doi: 10.1097/HCO.0000000000000623. Curr Opin Cardiol. 2019. PMID: 31169601 Review.
Low cholesterol syndrome and drug development.
Handhle A, Viljoen A, Ramachandran R, Wierzbicki AS. Handhle A, et al. Among authors: wierzbicki as. Curr Opin Cardiol. 2020 Jul;35(4):423-427. doi: 10.1097/HCO.0000000000000745. Curr Opin Cardiol. 2020. PMID: 32452920 Review.
391 results